HMT to support NIA’s study on brain metabolomic profiles in Alzheimer’s

23 October 2016 (Last Updated October 23rd, 2016 18:30)

Human Metabolome Technologies (HMT) has been contracted by the National Institute on Aging (NIA) to study brain metabolomic profiles in Alzheimer's disease.

Human Metabolome Technologies (HMT) has been contracted by the National Institute on Aging (NIA) to study brain metabolomic profiles in Alzheimer's disease.

Alzheimer's disease is the most common form of dementia that causes problems with memory, thinking and behaviour.

The study is aimed at accelerating the prevention and treatment of Alzheimer’s disease by combining clinical, genetic, epidemiologic, and imaging research with comprehensive metabolic phenotyping of human brain tissue.

NIA Laboratory of Behavioural Neuroscience's Unit of Clinical and Translational Neuroscience aims to improve understanding of disease mechanisms operating in Alzheimer's disease.

"Under the contract, HMT will provide high resolution metabolomic profiling of human brain tissue samples provided by the NIA."

The project will also identify novel biomarkers that might be predictive of disease before the onset of symptoms.

Under the contract, HMT will provide high resolution metabolomic profiling of human brain tissue samples provided by the NIA.

The company uses unique capillary electrophoresis mass spectrometry platforms to measure absolute and relative levels of metabolites associated with many pathways critical in the pathogenesis of AD.

The NIA is a division of the US National Institutes of Health (NIH) and its mission is to understand the nature of ageing and to extend the healthy, active years of life.

It supports and conducts research on ageing processes, age-related diseases, special problems and needs of the aged.